Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis.

Weinreich SS, Vrinten C, Kuijpers MR, Lipka AF, Schimmel KJM, van Zwet EW, Gispen-de Wied C, Hekster YA, Verschuuren JJGM, Cornel MC.

Orphanet J Rare Dis. 2017 May 12;12(1):88. doi: 10.1186/s13023-017-0636-y.

2.

Ephedrine treatment for autoimmune myasthenia gravis.

Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJ.

Neuromuscul Disord. 2017 Mar;27(3):259-265. doi: 10.1016/j.nmd.2016.11.009. Epub 2016 Nov 18.

3.

Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials.

Vrinten C, Lipka AF, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJ.

BMJ Open. 2015 Jul 16;5(7):e007863. doi: 10.1136/bmjopen-2015-007863.

4.

Authors' response to the letter from Kalleian Eserian et al.

van Riet-Nales DA, Doeve ME, Nicia AE, Teerenstra S, Notenboom K, Hekster YA, van den Bemt BJ.

Int J Pharm. 2015 Jan 30;478(2):682-3. doi: 10.1016/j.ijpharm.2014.11.006. Epub 2014 Nov 11.

PMID:
25445969
5.

The accuracy, precision and sustainability of different techniques for tablet subdivision: breaking by hand and the use of tablet splitters or a kitchen knife.

van Riet-Nales DA, Doeve ME, Nicia AE, Teerenstra S, Notenboom K, Hekster YA, van den Bemt BJ.

Int J Pharm. 2014 May 15;466(1-2):44-51. doi: 10.1016/j.ijpharm.2014.02.031. Epub 2014 Feb 21.

6.

Controlled release of morphine from a poloxamer 407 gel.

Jansen MM, Verzijl JM, Burger DM, Hekster YA.

Int J Pharm. 2013 Aug 16;452(1-2):266-9. doi: 10.1016/j.ijpharm.2013.05.032. Epub 2013 May 21.

PMID:
23707252
7.

The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.

van den Bemt BJ, den Broeder AA, Wolbink GJ, van den Maas A, Hekster YA, van Riel PL, Benraad HB, van den Hoogen FH.

Br J Clin Pharmacol. 2013 Dec;76(6):939-45. doi: 10.1111/bcp.12142.

8.

Treatment for neuropathic pain in patients with cancer: comparative analysis of recommendations in national clinical practice guidelines from European countries.

Piano V, Verhagen S, Schalkwijk A, Hekster Y, Kress H, Lanteri-Minet M, Burgers J, Treede RD, Engels Y, Vissers K.

Pain Pract. 2014 Jan;14(1):1-7. doi: 10.1111/papr.12036. Epub 2013 Jan 30. Review.

PMID:
23360414
9.

Diagnosing neuropathic pain in patients with cancer: comparative analysis of recommendations in national guidelines from European countries.

Piano V, Verhagen S, Schalkwijk A, Burgers J, Kress H, Treede RD, Hekster Y, Lanteri-Minet M, Engels Y, Vissers K.

Pain Pract. 2013 Jul;13(6):433-9. doi: 10.1111/papr.12018. Epub 2012 Dec 19. Review.

PMID:
23279302
10.

Guidelines for neuropathic pain management in patients with cancer: a European survey and comparison.

Piano V, Schalkwijk A, Burgers J, Verhagen S, Kress H, Hekster Y, Lanteri-Minet M, Engels Y, Vissers K.

Pain Pract. 2013 Jun;13(5):349-57. doi: 10.1111/j.1533-2500.2012.00602.x. Epub 2012 Oct 16. Review.

PMID:
23067004
11.

[Pitfalls in the treatment of neuropathic pain in patients with cancer].

Schalkwijk A, Verhagen CA, Engels Y, Hekster YA, Vissers KC.

Ned Tijdschr Geneeskd. 2011;155:A2494. Dutch.

PMID:
21382205
12.

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

van den Bemt BJ, den Broeder AA, Wolbink GJ, Hekster YA, van Riel PL, Benraad B, van den Hoogen FH.

BMC Musculoskelet Disord. 2011 Jan 13;12:12. doi: 10.1186/1471-2474-12-12.

13.

Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis.

van den Bemt BJ, den Broeder AA, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W.

Scand J Rheumatol. 2011 May;40(3):192-6. doi: 10.3109/03009742.2010.517214. Epub 2010 Oct 26.

PMID:
20977385
14.

Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.

van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W.

J Rheumatol. 2009 Oct;36(10):2164-70. doi: 10.3899/jrheum.081204. Epub 2009 Sep 1.

PMID:
19723906
15.

Requirements for generic anti-epileptic medicines: a regulatory perspective.

Maliepaard M, Hekster YA, Kappelle A, van Puijenbroek EP, Elferink AJ, Welink J, Gispen-de Wied CC, Lekkerkerker FJ.

J Neurol. 2009 Dec;256(12):1966-71. doi: 10.1007/s00415-009-5231-2. Epub 2009 Jul 15. Review. No abstract available.

16.

The impact of side effects on long-term retention in three new antiepileptic drugs.

Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Majoie M, Schellekens A, de Krom M, Aldenkamp AP.

Seizure. 2009 Jun;18(5):327-31. doi: 10.1016/j.seizure.2008.11.006. Epub 2008 Dec 24.

17.

Drug treatment-related factors of inadequate seizure control.

Handoko KB, Zwart-van Rijkom JE, Visee HF, Hermens WA, Hekster YA, Egberts TC.

Epilepsy Behav. 2008 Oct;13(3):545-8. doi: 10.1016/j.yebeh.2008.04.007. Epub 2008 Jul 25.

PMID:
18657477
18.

Influence of chemical structure on hypersensitivity reactions induced by antiepileptic drugs: the role of the aromatic ring.

Handoko KB, van Puijenbroek EP, Bijl AH, Hermens WA, Zwart-van Rijkom JE, Hekster YA, Egberts TC.

Drug Saf. 2008;31(8):695-702.

PMID:
18636788
19.

Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription.

Verhagen CC, Niezink AG, Engels YY, Hekster YY, Doornebal JJ, Vissers KC.

Pain Pract. 2008 May-Jun;8(3):157-63. doi: 10.1111/j.1533-2500.2008.00189.x. Epub 2008 Mar 27.

PMID:
18373512
20.

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.

van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.

Ann Rheum Dis. 2008 Dec;67(12):1697-701. doi: 10.1136/ard.2007.083683. Epub 2008 Jan 31.

PMID:
18245109
21.

A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.

Knoester PD, Deckers CL, Termeer EH, Boendermaker AJ, Kotsopoulos IA, de Krom MC, Keyser T, Renier WO, Hekster YA, Severens HL.

Value Health. 2007 May-Jun;10(3):173-82.

22.

The complexities of ethical evaluation of genomics research.

Hoedemaekers R, Gordijn B, Hekster Y, van Agt F.

HEC Forum. 2006 Mar;18(1):18-36. No abstract available.

PMID:
17076127
23.

Movement disorders induced by gastrointestinal drugs: two paediatric cases.

Elzinga-Huttenga J, Hekster Y, Bijl A, Rotteveel J.

Neuropediatrics. 2006 Apr;37(2):102-6.

PMID:
16773510
24.

Non-compliance on the part of the professional community with a national guideline: an argumentative policy analysis.

Moret-Hartman M, Knoester PD, Hekster YA, van der Wilt GJ.

Health Policy. 2006 Oct;78(2-3):353-9. Epub 2006 Jan 18.

PMID:
16387386
25.
26.

Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.

Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM.

Clin Pharmacol Ther. 2005 Dec;78(6):664-74.

PMID:
16338282
27.

Cost-effectiveness of add-on lamotrigine therapy in clinical practice.

Knoester PD, Boendermaker AJ, Egberts AC, Hekster YA, Keyser A, Severens JL, Renier WO, Deckers CL.

Epilepsy Res. 2005 Dec;67(3):143-51. Epub 2005 Nov 8.

PMID:
16288850
28.

[Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression].

Lekkerkerker JF, Schobben AF, van Dissel JT, Hekster YA, Hoes AW, Mulder GJ, Neef C, Peeters MF, van Ree JM, Rosmalen CF, Schellekens H, Schellens JH, Silberbusch J.

Ned Tijdschr Geneeskd. 2005 Aug 13;149(33):1870-1; author reply 1871-2. Dutch. No abstract available.

PMID:
16128186
29.

TDM: therapeutic drug measuring or therapeutic drug monitoring?

Droste JA, Koopmans PP, Hekster YA, Burger DM.

Ther Drug Monit. 2005 Aug;27(4):412-6.

PMID:
16044095
30.

Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study.

Knoester PD, Keyser A, Renier WO, Egberts AC, Hekster YA, Deckers CL.

Epilepsy Res. 2005 Jun;65(1-2):93-100.

PMID:
16023833
31.

Volume and market share of anti-epileptic drugs in The Netherlands: impact of new drugs.

Knoester P, Deckers C, van der Vaart R, Leufkens B, Hekster Y.

Pharm World Sci. 2005 Apr;27(2):129-34.

PMID:
15999925
32.

Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice.

Wilting I, Movig KL, Moolenaar M, Hekster YA, Brouwers JR, Heerdink ER, Nolen WA, Egberts AC.

Bipolar Disord. 2005 Jun;7(3):274-80.

PMID:
15898965
33.

Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.

Droste JA, Verweij-van Wissen CP, Kearney BP, Buffels R, Vanhorssen PJ, Hekster YA, Burger DM.

Antimicrob Agents Chemother. 2005 Feb;49(2):680-4.

34.

Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers.

la Porte C, Verweij-van Wissen C, van Ewijk N, Aarnoutse R, Koopmans P, Reiss P, Stek M Jr, Hekster Y, Burger D.

J Clin Pharmacol. 2005 Feb;45(2):211-8.

PMID:
15647414
35.

Diffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice.

Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA.

Eur J Clin Pharmacol. 2004 Dec;60(10):751-8. Epub 2004 Nov 20.

PMID:
15619137
36.

Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.

la Porte CJ, de Graaff-Teulen MJ, Colbers EP, Voncken DS, Ibanez SM, Koopmans PP, Hekster YA, Burger DM.

Br J Clin Pharmacol. 2004 Dec;58(6):632-40.

37.

Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not.

Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA.

Pharmacoepidemiol Drug Saf. 2005 Feb;14(2):107-12.

PMID:
15386696
38.

[A patient with lessened sensitivity to acenocoumarol during a period of enteral feeding].

van Iersel MD, Blenke AA, Kremer HP, Hekster YA.

Ned Tijdschr Geneeskd. 2004 Jun 5;148(23):1155-7. Dutch.

PMID:
15211967
39.

Improving the process of antibiotic therapy in daily practice: interventions to optimize timing, dosage adjustment to renal function, and switch therapy.

Vogtländer NP, Van Kasteren ME, Natsch S, Kullberg BJ, Hekster YA, Van Der Meer JW.

Arch Intern Med. 2004 Jun 14;164(11):1206-12.

PMID:
15197046
40.

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.

la Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom K, Boeree MJ, Koopmans PP, Hekster YA, Burger DM.

Antimicrob Agents Chemother. 2004 May;48(5):1553-60.

41.

Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands.

Knoester PD, Belitser SV, Deckers CL, Keyser A, Renier WO, Egberts AC, Hekster YA.

J Clin Pharm Ther. 2004 Apr;29(2):131-8.

PMID:
15068401
42.

Selecting outcome parameters in studies aimed at improving rational use of antibiotics - practical considerations.

Natsch S, Kullberg BJ, Hekster YA, van der Meer JW.

J Clin Pharm Ther. 2003 Dec;28(6):475-8.

PMID:
14651670
43.

Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.

Aarnoutse RE, Wasmuth JC, Fätkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM, Rockstroh JK.

Antivir Ther. 2003 Aug;8(4):309-14.

PMID:
14518700
44.

Selection criteria for the clinical use of the newer antiepileptic drugs.

Deckers CL, Knoester PD, de Haan GJ, Keyser A, Renier WO, Hekster YA.

CNS Drugs. 2003;17(6):405-21. Review.

PMID:
12697000
45.

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM.

Drugs. 2003;63(8):741-53. Review.

PMID:
12662123
46.

Increase in drug use after admission to Dutch nursing homes.

Koopmans RT, van der Borgh JP, Bor JH, Hekster YA.

Pharm World Sci. 2003 Feb;25(1):30-4.

PMID:
12661475
47.

Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM.

J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):287-91.

PMID:
12626888
48.

Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.

Aarnoutse RE, Droste JA, van Oosterhout JJ, Koopmans PP, Popescu M, Reiss P, Hekster YA, Burger DM.

Br J Clin Pharmacol. 2003 Feb;55(2):115-25.

49.

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance.

Hugen PW, Burger DM, Aarnoutse RE, Baede PA, Nieuwkerk PT, Koopmans PP, Hekster YA.

Ther Drug Monit. 2002 Oct;24(5):579-87.

PMID:
12352928
50.

Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast.

Hugen PW, Burger DM, Koopmans PP, Stuart JW, Kroon FP, van Leusen R, Hekster YA.

Pharm World Sci. 2002 Jun;24(3):83-6.

PMID:
12136744

Supplemental Content

Loading ...
Support Center